Daily pill tested to hold back rare bone cancer in kids
NCT ID NCT06341712
Summary
This study tested whether adding a daily pill called cabozantinib to standard supportive care could help children and young adults with osteosarcoma (bone cancer) that could not be fully removed by surgery. Participants, who had already finished chemotherapy, were randomly assigned to receive either the pill plus supportive care or supportive care alone. The main goal was to see if the pill could delay the cancer from getting worse.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOSARCOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
AOU Città della Salute e della Scienza di Torino
Piemonte, Italy
-
Amsterdam UMC - Locatie AMC
Amsterdam, Netherlands
-
Birmingham Children's Hospital
Birmingham, United Kingdom
-
Centre Oscar Lambret
Lille, France
-
Children's Hospital of the King's Daughters
Norfolk, Virginia, 23507, United States
-
Dr. von Haunerschen Kinderspital
München, Germany
-
Hospital Infantil Universitario Nino Jesus
Madrid, Spain
-
Hospital Universitari i Politecnic La Fe
Valencia, Spain
-
Hospital Universitario Vall d'Hebron
Barcelona, Spain
-
Hospital de La Santa Creu i Sant Pau
Barcelona, Spain
-
Instytut Matki i Dziecka
Warsaw, Poland
-
McGill University Health Centre - Centre for Innovative Medicine
Québec, Canada
-
Ospedale Ortopedico Rizzoli di Bologna
Bologna, Italy
-
Princess Margaret cancer center
Toronto, Canada
-
University Hospital Gent
Ghent, Belgium
-
Universitätsmedizin Mainz
Mainz, Germany
Conditions
Explore the condition pages connected to this study.